Skip to main content

Table 2 Association of cfDNA levels with features of disease severity in NAFLD patients

From: Correlation of cell-free DNA plasma concentration with severity of non-alcoholic fatty liver disease

Parameter cfDNA fragment Median (range) p value
Liver stiffness   ≤7.0 kPa (n = 45) >7.0 kPa (n = 13)  
90 bp 3.16 (1.29–7.31) 6.05 (2.41–23.13) <0.001
222 bp 11.32 (6.05–18.28) 14.41 (9.27–22.90) 0.0041
  ≤9.6 kPa (n = 48) >9.6 kPa (n = 10)  
90 bp 3.22 (1.29–8.17) 5.78 (2.41–23.13) 0.011
222 bp 11.35 (6.05–19.74) 14.27 (9.27–22.90) 0.059
Inflammatory activity   ALT ≤ ULN (n = 32) ALT > ULN (n = 26)  
90 bp 3.08 (1.29–23.13) 3.93 (2.19–8.62) 0.26
222 bp 11.20 (6.92–22.90) 12.89 (6.05–19.74) 0.23
  AST ≤ ULN (n = 40) AST > ULN (n = 18)  
90 bp 3.05 (1.29–8.17) 5.18 (1.38–23.13) 0.038
222 bp 11.32 (6.05–19.74) 13.79 (8.66–22.90) 0.14
  Ferritin ≤ ULN (n = 40) Ferritin > ULN (n = 17)  
90 bp 3.21 (1.29–8.17) 4.70 (2.19–23.13) 0.026
222 bp 11.20 (6.05–19.74) 13.25 (10.0–22.90) 0.0071
Steatosis   CAP ≤ 282 dB/m (n = 16) CAP > 282 dB/m (n = 42)  
90 bp 3.51 (1.38–7.56) 3.71 (1.29–23.13) 0.12
222 bp 12.00 (6.05–18.28) 11.49 (6.91–22.90) 0.083
  Fat fraction Fat fraction  
  (1 H-MRS) ≤10% (n = 25) (1 H-MRS) >10% (n = 33)  
90 bp 2.97 (1.28–8.62) 3.90 (1.38–23.13) 0.13
222 bp 11.35 (6.92–18.28) 12.35 (6.05–22.90) 0.34
  1. Values presented as median and range (ng/mL), p-values are taken from a linear mixed model with sex as a covariate and PCR-batch as a random term
  2. 1 H-MRS single-proton magnetic resonance spectroscopy, CAP controlled attenuation parameter, rHLC relative hepatic lipid content, ALT alanine aminotransferase, AST aspartate aminotransferase, ULN upper limit of normal